Coherus receives US FDA approval for Neulasta biosimilar, pricing 33% lower 09-Nov-2018 By Ben Hargreaves The company will launch Udenyca onto the US market on January 3, 2019, to compete with Amgen’s originator product and Mylan’s rival biosimilar.